Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left">Parameter</td><td class="align_center">Control versus total</td><td class="align_center">Prostatitis versus BPH</td><td class="align_center">BPH versus P.Ca</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">PSA</td><td class="align_center">100%</td><td class="align_center">76.6%</td><td class="align_center">59.2%</td></tr><tr><td class="align_left">PAP</td><td class="align_center">82.4%</td><td class="align_center">90%</td><td class="align_center">83.35</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>The table showed the percentage of diagnostic efficiency of PSA and PAP in cases and controls. Serum PSA showed 100% DE in total cases and control whereas PAP showed only 82.4%. PSA showed DE of 76.6% and 59.2% in prostatitis versus BPH and BPH versus P.Ca, respectively, whereas DE of PAP was 90% and 83.3% in the above groups.<br/></td></tr></table>

The percentage of diagnostic efficiency (DE).

Prostate Cancer

tab4

Table 4

Table 4: Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus 

Table 4 | Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus 